A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 492 participants.

Also called NCT06926660

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 492 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06926660
  • EU CT 2024-518457-42-00
  • WHO UTN U1111-1314-0083
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Puerto Rico, South Korea, Spain, Taiwan, Thailand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06926660. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-18 (actual); primary completion 2026-08-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Intervention (Drug)
Vicadrostat
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo matching vicadrostat
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct06926660
Content hash
57beea4d66fe6d580af3de78f6e0e3c74d74d2ef0a318c1b75471a91706b06cf